MANNARELLI, CARMELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.395
EU - Europa 3.014
AS - Asia 1.680
SA - Sud America 162
Continente sconosciuto - Info sul continente non disponibili 119
AF - Africa 41
OC - Oceania 14
Totale 9.425
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.330
RU - Federazione Russa 896
IT - Italia 665
PL - Polonia 630
SG - Singapore 489
CN - Cina 447
HK - Hong Kong 238
IE - Irlanda 165
VN - Vietnam 161
KR - Corea 129
BR - Brasile 125
SE - Svezia 124
DE - Germania 122
FR - Francia 98
FI - Finlandia 88
GB - Regno Unito 70
IN - India 58
CH - Svizzera 57
CA - Canada 40
JO - Giordania 36
NL - Olanda 29
ES - Italia 19
ID - Indonesia 19
JP - Giappone 18
TW - Taiwan 18
AU - Australia 14
IQ - Iraq 14
BE - Belgio 10
AR - Argentina 8
BD - Bangladesh 8
CI - Costa d'Avorio 8
MX - Messico 8
NP - Nepal 8
CZ - Repubblica Ceca 7
NG - Nigeria 7
AT - Austria 6
EC - Ecuador 6
RO - Romania 6
VE - Venezuela 6
ZA - Sudafrica 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
PH - Filippine 5
PK - Pakistan 5
SA - Arabia Saudita 5
CL - Cile 4
EG - Egitto 4
KE - Kenya 4
MY - Malesia 4
TR - Turchia 4
UA - Ucraina 4
AL - Albania 3
JM - Giamaica 3
LT - Lituania 3
PY - Paraguay 3
UY - Uruguay 3
BH - Bahrain 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HU - Ungheria 2
KZ - Kazakistan 2
LV - Lettonia 2
MU - Mauritius 2
NO - Norvegia 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
AZ - Azerbaigian 1
BJ - Benin 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BT - Bhutan 1
BW - Botswana 1
BY - Bielorussia 1
CU - Cuba 1
DK - Danimarca 1
ET - Etiopia 1
EU - Europa 1
GR - Grecia 1
HN - Honduras 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
MA - Marocco 1
MT - Malta 1
NI - Nicaragua 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
VG - Isole Vergini Britanniche 1
YT - Mayotte 1
Totale 9.309
Salva come PNG Salva come JPEG
Città #
Santa Clara 845
Warsaw 627
Ashburn 515
Singapore 334
Fairfield 332
Chandler 197
Hong Kong 195
Dublin 165
San Jose 165
Woodbridge 165
Seattle 151
Seoul 126
Houston 124
Beijing 121
Wilmington 118
Cambridge 108
Florence 101
Ann Arbor 94
Milan 70
Hefei 61
Altamura 60
Bern 55
Buffalo 55
Council Bluffs 55
Lawrence 55
Los Angeles 55
Munich 55
Dallas 50
Ho Chi Minh City 48
Princeton 48
Lauterbourg 42
Rome 40
Hanoi 38
Mumbai 36
Helsinki 34
Boston 33
New York 33
The Dalles 32
Turku 29
Bremen 27
Shanghai 26
Kent 23
Paris 23
London 22
Clifton 20
San Diego 20
Moscow 19
Boardman 17
Tokyo 16
Atlanta 15
Frankfurt am Main 15
Melbourne 14
Taipei 14
Jakarta 13
Phoenix 13
Dong Ket 12
Redondo Beach 12
Medford 11
São Paulo 11
Brussels 10
Figino 10
Orem 10
Palermo 10
Toronto 10
Brooklyn 9
Da Nang 9
Ealing 9
Tianjin 9
Abidjan 8
Baghdad 8
Barcelona 8
Montreal 8
Brescia 7
Chicago 7
Düsseldorf 7
Falls Church 7
Fiesole 7
Guangzhou 7
Modena 7
Prague 7
Turin 7
Abuja 6
Amsterdam 6
Charlotte 6
Dearborn 6
Elk Grove Village 6
Miano 6
Naples 6
Norwalk 6
Pian di Scò 6
Pinole 6
Pune 6
Verona 6
Vienna 6
Austin 5
Cagliari 5
Chennai 5
Genoa 5
Haiphong 5
Hillsboro 5
Totale 6.099
Salva come PNG Salva come JPEG
Nome #
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 402
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells 357
Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms 351
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 335
“MiRNA expression in Primary Myelofibrosis: characterization and pathophysiology implications” 323
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells 274
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 264
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 251
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 233
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 232
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation 230
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 222
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 222
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 220
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 212
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 212
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 203
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 200
Mutations and prognosis in primary myelofibrosis. 199
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 199
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 197
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 197
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 194
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 193
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 191
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 190
Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients 190
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 180
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis 177
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 177
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 176
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 172
Novel insights into myelofibrosis pathophysiology and treatment 168
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 167
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis 165
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. 163
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis. 162
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 162
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 161
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 157
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease 154
Diagnostic and therapeutic challenges in mast cell sarcoma 152
Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. 152
The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. 148
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 139
Totale 9.425
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.453
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.453
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022294 0 0 36 8 16 19 9 41 11 16 52 86
2022/2023959 67 177 57 72 66 135 106 60 95 18 32 74
2023/2024471 25 35 61 22 51 55 18 113 11 21 38 21
2024/20252.560 72 249 161 426 670 386 48 106 115 86 116 125
2025/20262.469 335 297 199 162 317 94 316 99 152 166 66 266
2026/2027562 103 368 91 0 0 0 0 0 0 0 0 0
Totale 9.425